Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis — Stella

Recruiting

Back to Multiple Sclerosis trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

France

CHU de Bordeaux - service de neurologie, Bordeaux

Key details

Sponsor

University Hospital, Bordeaux

Collaborators

University of Bordeaux

Enrollment target

~150 participants

Started

September 2021

Primary completion

September 2026

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov